Publications by authors named "Gary Binder"

Claim this Profile
I
Ivosidenib or venetoclax combined with hypomethylating agents in -mutated acute myeloid leukemia: a real-world study.
Curtis A Lachowiez, B Douglas Smith, Alexander Joseph Ambinder, Gary Binder, Anne Angiolillo

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial.
Amir T Fathi, B Douglas Smith, Anne Angiolillo, Gary Binder, Assaf Vestin

Leuk Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
Lee Schwartzberg, Rudolph M Navari, Kathryn J Ruddy, Thomas W LeBlanc, Rebecca Clark-Snow, Gary Binder

Support Care Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction.
Josephine Harrington, Jie-Lena Sun, Gregg C Fonarow, Stephen B Heitner, Punag H Divanji, Gary Binder

J Am Heart Assoc· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.
Rudolph Navari, Gary Binder, Alex Molasiotis, Jørn Herrstedt, Eric J Roeland

Oncologist· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Rudolph M Navari, Gary Binder, Erminio Bonizzoni, Rebecca Clark-Snow, Silvia Olivari

Future Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort Study.
Christiane Querfeld, Theresa Pacheco, Bradley Haverkos, Gary Binder, James Angello

Front Med (Lausanne)· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
Rudolph M Navari, Kathryn J Ruddy, Thomas W LeBlanc, Ryan Nipp, Rebecca Clark-Snow, Gary Binder

Oncologist· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy.
Eric J Roeland, Kathryn J Ruddy, Thomas W LeBlanc, Ryan D Nipp, Gary Binder

J Natl Compr Canc Netw· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Marc Botteman, Katharina Nickel, Shelby Corman, Marco Turini, Gary Binder

Support Care Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care.
Rudolph M Navari, Kathryn J Ruddy, Thomas W LeBlanc, Rebecca Clark-Snow, Rita J Wickham, Gary Binder

JCO Oncol Pract· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Sang Hee Park, Gary Binder, Shelby Corman, Marc Botteman

J Med Econ· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes.
Amy E DeZern, Gary Binder, Quanhong Ni, Michael McGuire, B Douglas Smith

Leuk Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.
Amy E DeZern, Gary Binder, Syed Rizvi, Frank A Corvino, Steven R Arikian

Leuk Lymphoma· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence.
Christopher R Cogle, Sheila R Reddy, Eunice Chang, Elya Papoyan, Michael S Broder, Gary Binder

Leuk Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of endocervical sampling following loop excision of high grade intraepithelial neoplasia.
Yiwen Cui, Haleh Sangi-Haghpeykar, Bruce Patsner, Jennifer M M Bump, Marian Y Williams-Brown, Gary L Binder

Gynecol Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma.
Claire Lee, Matthew Grigorian, Ryan Nolan, Gary Binder, Gary Rice

J Med Econ· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Steven R Arikian, Dejan Milentijevic, Gary Binder, Craig J Gibson, X Henry Hu

Curr Med Res Opin· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total cost comparison in relapsed/refractory multiple myeloma.
Brian Durie, Gary Binder, Chris Pashos, Zeba Khan, Mohamad Hussein

J Med Econ· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis